PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation

Patients with secondary acute myeloid leukemia (sAML) arising from myelodysplastic syndromes have a poor prognosis marked by an increased resistance to chemotherapy. An urgent need exists for adjuvant treatments that can enhance or replace current therapeutic options. Here we show the potential of L...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Chao, Yu, Mengxia, Ren, Yanling, Li, Kongfei, Maggio, Dominic M., Mei, Chen, Ye, Li, Wei, Juying, Jin, Jie, Zhuang, Zhengping, Tong, Hongyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460144/
https://www.ncbi.nlm.nih.gov/pubmed/28588271
http://dx.doi.org/10.1038/s41598-017-03058-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460144/
https://www.ncbi.nlm.nih.gov/pubmed/28588271
http://dx.doi.org/10.1038/s41598-017-03058-4

Ejemplares similares